RECEIVED
CENTRAL FAX CENTER
AUG 2 3 2006

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims

1. (currently amended) - A ligand specific for human epithelial cancer cells, wherein said ligand has the chemical structure of ~~$cX_2GX_4GX_6X_7c$~~ cXGXGXXc, in which "c" is D-cysteine; ~~"X_2", "X_4", "X_6", and "X_7" are~~ "X" is an amino acids selected from the group consisting of L-amino acids~~, D-amino acids, and unnatural amino acids~~; and "G" is glycine~~; and further, wherein "X_2" is either polar and neutral or polar and acidic, and wherein "X_4" is hydrophobic~~.

2. (original) - The ligand of claim 1, wherein said epithelial cells are ovarian cancer cells.

3. (currently amended) - A ligand specific for human non-epithelial cancer cells, wherein said ligand has the chemical structure of $cX_2GX_4GX_6X_7c$, in which "c" is D-cysteine; ~~"X_2", "X_4", "X_6", and "X_7" are amino acids selected from the group consisting of L-amino acids, D-amino acids, and unnatural amino acids; and "G" is glycine; and further, wherein "X_2" is either polar and neutral or polar and acidic, and wherein "X_4" is hydrophobic~~ "G" is glycine; "X_2" is an amino acid selected from the group consisting of D,d,N, n, S,Q,q,T, HoSer, Cit, E, e, HoCit, Hyp, Aad, Lys(Ac), A, 4-Pal, D-3-Pal, Pra, D-Pra, Y, Aib, M, Phe(4-CN), Tyr(3-NO_2), Tyr(Me), Phe(4-NO_2), Bug, Ach, Tyr(3,5-I), Aic, Phe(3-Cl), Chg, Bta, Bpa, Phe(3,4-Cl), Hyp(Bzl), and Cha; and "X_4", "X_6" and "X_7" are amino acids selected from the group consisting of N, S, Q, T, HoSer, Cit, HoCit, Hyp, H, A, Pal, D-3-Pal, Pra, R, Y, Aib, Abu, P, M, V, Nva, Tyr(3-NO_2), W, Phg, Phe(4-NO_2), Bug, I, Ach, L, Nle, Phe(4-Me), Aic, Phe(3-Cl), HoPhe, Chg, Bta, Bpa, 2-Nal, 1-Nal, Phe(3,4-Cl), Hyp(Bzl), and Cha .

4. (original) - The ligand of claim 3, wherein said non-epithelial cells are brain cancer cells.

5. (canceled)

6. (canceled)

7. (canceled)

8. (canceled)

9. (canceled)

10. (new) - The ligand of claim 1, wherein said ligand has the chemical structure of cDGLGDDc.

11. (new) - A ligand specific for human epithelial cancer cells, wherein said ligand has the chemical structure of $cX_2GX_4GX_6X_7c$, in which "c" is D-cysteine, "G" is glycine; "X_2" is an amino acid selected from the group consisting of D,d,N, n, S,Q,q,T, HoSer, Cit, E, e, HoCit, Hyp, Aad, Lys(Ac), A, 4-Pal, D-3-Pal, Pra, D-Pra, Y, Aib, M, Phe(4-CN), Tyr(3-NO_2), Tyr(Me), Phe(4-NO_2), Bug, Ach, Tyr(3,5-I), Aic, Phe(3-Cl), Chg, Bta, Bpa, Phe(3,4-Cl), Hyp(Bzl), and Cha; and "X_4", "X_6" and "X_7"are amino acids selected from the group consisting of N, S, Q, T, HoSer, Cit, HoCit, Hyp, H, A, Pal, D-3-Pal, Pra, R, Y, Aib, Abu, P, M, V, Nva, Tyr(3-NO_2), W, Phg, Phe(4-NO_2), Bug, I, Ach, L, Nle, Phe(4-Me), Aic, Phe(3-Cl), HoPhe, Chg, Bta, Bpa, 2-Nal, 1-Nal, Phe(3,4-Cl), Hyp(Bzl), and Cha.

12. (new) - The ligand of claim 11, wherein said ligand has the chemical structure of c-d-G-HoCit-G-P-Q-c.

13. (new) - The ligand of claim 3, wherein said ligand has the chemical structure of cDGLGDDc.

14. (new) - The ligand of claim 3, wherein said ligand has the chemical structure of cDGWGPNc.